Managing skin reactions to targeted cancer therapy
Many clinicians are tempted to withhold or discontinue an EGFR inhibitor when the skin reaction appears or when they can’t control it. Yet, because…




*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.